Clinical trial
An Single-arm Open-label Phase II Study of Decitabine Plus Penpulimab as Second-line Therapy for Advanced Esophageal Squamous Cell Carcinoma Treated With PD-1 Blockade
NCT05265962 is registered in ClinicalTrials.gov with The First Affiliated Hospital of Zhengzhou University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Single-arm Open-label Phase II Study of Decitabine Plus Penpulimab as Second-line Therapy for Advanced Esophageal Squamous Cell Carcinoma Treated With PD-1 Blockade
- Lead sponsor
- The First Affiliated Hospital of Zhengzhou University
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- December 1, 2022
- Completion date
- December 31, 2024
- Enrollment
- 85 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.